1. Home
  2. MEIP vs COSM Comparison

MEIP vs COSM Comparison

Compare MEIP & COSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MEIP
  • COSM
  • Stock Information
  • Founded
  • MEIP 2000
  • COSM 2009
  • Country
  • MEIP United States
  • COSM United States
  • Employees
  • MEIP N/A
  • COSM N/A
  • Industry
  • MEIP Biotechnology: Pharmaceutical Preparations
  • COSM Other Pharmaceuticals
  • Sector
  • MEIP Health Care
  • COSM Health Care
  • Exchange
  • MEIP Nasdaq
  • COSM Nasdaq
  • Market Cap
  • MEIP 13.3M
  • COSM 12.9M
  • IPO Year
  • MEIP 2003
  • COSM 2013
  • Fundamental
  • Price
  • MEIP $2.53
  • COSM $0.42
  • Analyst Decision
  • MEIP Hold
  • COSM
  • Analyst Count
  • MEIP 1
  • COSM 0
  • Target Price
  • MEIP N/A
  • COSM N/A
  • AVG Volume (30 Days)
  • MEIP 21.5K
  • COSM 185.7K
  • Earning Date
  • MEIP 05-13-2025
  • COSM 08-18-2025
  • Dividend Yield
  • MEIP N/A
  • COSM N/A
  • EPS Growth
  • MEIP N/A
  • COSM N/A
  • EPS
  • MEIP N/A
  • COSM N/A
  • Revenue
  • MEIP N/A
  • COSM $53,554,457.00
  • Revenue This Year
  • MEIP N/A
  • COSM $28.14
  • Revenue Next Year
  • MEIP N/A
  • COSM N/A
  • P/E Ratio
  • MEIP N/A
  • COSM N/A
  • Revenue Growth
  • MEIP 33.76
  • COSM N/A
  • 52 Week Low
  • MEIP $1.46
  • COSM $0.28
  • 52 Week High
  • MEIP $4.10
  • COSM $1.58
  • Technical
  • Relative Strength Index (RSI)
  • MEIP 78.43
  • COSM 45.07
  • Support Level
  • MEIP $2.21
  • COSM $0.42
  • Resistance Level
  • MEIP $2.95
  • COSM $0.47
  • Average True Range (ATR)
  • MEIP 0.15
  • COSM 0.03
  • MACD
  • MEIP 0.05
  • COSM -0.00
  • Stochastic Oscillator
  • MEIP 81.48
  • COSM 21.56

About MEIP MEI Pharma Inc.

MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.

About COSM Cosmos Health Inc.

Cosmos Health Inc is engaged in the nutraceuticals sector through its own proprietary lines of products 'Sky Premium Life' and 'Mediterranation'. Additionally, the firm is operating in the pharmaceutical sector through the provision of a broad line of branded over-the-counter drugs and branded and generic medicines. The company's focus will be on Branded Pharmaceuticals, Over-the-Counter medicines, and Generic Pharmaceuticals. It provides its products to wholesale drug distributors, wholesalers, and retail healthcare providers. The company's segment are Wholesale, Pharma Manufacturing, Nutraceuticals & Pharmaceuticals and Other. It derives maximum revenue from Wholesale Segment.

Share on Social Networks: